NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
News
MSD’s Keytruda shows benefit in oesophageal cancer trial
MSD’s Keytruda has shown promise in a late-stage trial testing its safety and efficacy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma.
Final NICE green light for Pfizer’s Mylotarg
Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine, as an option for untreated de novo CD33-positive acute myeloid leukaemia (AML).
NIHR streams £5m into global infectious diseases research
The National Institute for Health Research is streaming £5 million of global health funding into research looking at how infectious diseases spread and develop into epidemics in low- and middle-income countries.
Ipsen’s Cabometyx wins EU nod for liver cancer
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Lilly files lasmiditan for migraine
Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults.
Entry closes as countdown to the competition & awards ceremony begins
Entry has now closed for the inaugural PharmaTimes Medical & Scientific Awards, join us at the gala dinner awards ceremony where our winners will be revealed.
Priority review for Roche’s Tecentriq/Abraxane combo
US regulators are undertaking a priority review of Roche’s Tecentriq in combination with Abraxane for the treatment of triple-negative breast cancer.
Australian pharma Phebra sets up UK operations
Australian pharma Phebra has set up operations in the UK with the establishment of a new wholly-owned subsidiary company.
NHS to fund continuous blood glucose monitoring system
Tens of thousands of people with type I diabetes across the country are to benefit from “life-changing” glucose monitors on the NHS, NHS England has announced on World Diabetes Day.
UK launch for Mylan, Biocon insulin glargine biosimilar Semglee
Mylan and Biocon have announced the UK launch of Semglee – an approved biosimilar of reference medicine insulin glargine.
Pfizer loses landmark second medical use patent case
The UK Supreme Court has ruled against Pfizer in a long-running legal battle over the validity of a second medical use patent protecting pregabalin.
The Sales Awards ceremony draws closer – don’t miss out on the chance to book tickets
The PharmaTimes Sales Awards takes place on the 15th November – book your tickets now so that you don’t miss out on this ceremony that celebrates the very best the industry has to offer.
The Marketer of the Year awards ceremony draws closer – don’t miss out on the chance to book tickets
The PharmaTimes Marketer of the Year Awards takes place on the 15th November – book your tickets now so that you don’t miss out on this special 25th anniversary ceremony that celebrates the very best the industry has to offer.
The Communications Team of the Year awards ceremony draws closer – don’t miss out on the chance to book tickets
The PharmaTimes Communications of the Year Awards takes place on the 15th November – book your tickets now so that you don’t miss out on this ceremony that celebrates the very best the industry has to offer.
